WHO and INTERPOL agreement puts falsified medicines in focus

01

A cooperation framework, with medicines among its priorities

The October 16 announcement links public-health and policing work. Its scope includes falsified medicines, vaccines and devices, alongside other health and security threats. It describes cooperation between the organizations, rather than announcing a recall of a named medicine or batch.

For a reader deciding what a headline means for their own medicine, that distinction comes first: an institutional agreement and an individual product alert answer different questions.

Sources for this section: [1]

02

A convincing package is not proof

WHO warns that some falsified products closely resemble genuine ones. FDA also describes online storefronts that imitate legitimate pharmacies. Appearance can raise a concern, but cannot settle authenticity.

Keep three questions separate: who supplied the medicine, whether its details match what was expected, and whom to contact about a concern. Treating a neat website or familiar-looking box as the answer to all three leaves the important checks unfinished.

Sources for this section: [2] [3]

03

Check the seller before relying on the label

1. Use a licensed supplier. For a U.S. online pharmacy, FDA highlights a valid prescription requirement, a U.S. address and phone number, a licensed pharmacist and state-board licensing.
2. Verify the registration through an official resource. FDA's state-board directory includes Puerto Rico and other U.S. jurisdictions. Follow the relevant authority's lookup route; a badge on the seller's page is not the lookup itself. Other countries have their own regulators.
3. Compare the inner and outer packaging's batch and expiry details, and look for damage or unexpected appearance. These checks can identify inconsistencies; they do not authenticate the contents.

This sequence keeps the evidence organized. Seller verification addresses the supply route; a packaging comparison addresses the particular item. Neither question should disappear merely because the other seems reassuring.

Sources for this section: [2] [3] [4]

04

Turn a suspicion into a useful conversation

WHO advises discussing a suspected product with a pharmacist or another healthcare professional and reporting the concern to the national medicines regulator. Suspected treatment failure or an adverse reaction warrants prompt professional attention.

A practical way to organize that conversation is to identify the medicine and supplier, describe the specific discrepancy, and say whether the concern involves packaging, an unexpected effect or failure to work. Ask: “Who can check this item, and what should I do about my treatment while it is checked?” This article cannot make that individual treatment decision.

For U.S. readers, FDA distinguishes reporting an unsafe medicine-selling website from reporting a medicine's adverse effects through MedWatch. Choosing the relevant route helps make clear what you are reporting.

Prepare a current medication list for the conversation

Sources for this section: [2] [3]

05

What to watch after the announcement

The agreement is evidence of an announced collaboration, not a measurement of its success. A later report of an operation, a regulator's product alert and an evaluation of outcomes would each need their own evidence.

Kadomony's interpretation is to read the current announcement at that level. It does not establish that a particular reader's medicine is affected, and it does not replace a product-specific notice or advice from the professional responsible for their care.

How Kadomony separates health news from clinical guidance

Sources for this section: [1]